Parry-Romberg Syndrome Market Research Report - Global Forecast Till 2027

Parry-Romberg Syndrome Market Information: By Diagnosis (Physical Examination, MRI Scan, Serum Test, and others), By Treatment (Drug Treatment, Surgery, others), and By End User (Hospitals & Clinics, Physical Therapists, others) - Global Forecast till 2027

ID: MRFR/Pharma/2986-HCR | February 2021 | Region: Global | 115 pages

Please note that the assessment period of report has been updated from 2023 to 2027. Cordially fill the sample form for updated data.

Market Scenario
Parry-Romberg syndrome is also known as progressive hemifacial atrophy. It is a rare disease, which is characterized by the shrinking and degeneration of the tissues beneath the skin. The changes and deterioration spread slowly and it occurs on one side and rarely extends to other parts of the body. General symptoms, includes facial changes, which involves the tissues above the upper jaw or between the nose and the upper corner of the lip and subsequently progress to the mouth, areas around the eye, the ear, and the neck. Currently, no cure and treatments are available for the parry-Romberg syndrome.


Increasing prevalence of skin diseases, neurological abnormalities, and eye defects are the major driving factors for the growth of the market during the forecast period. Moreover, oral diseases also boost the market growth as the tissues of mouth, including the tongue, gingiva, teeth, and soft palate are commonly involved in Parry-Romberg syndrome.


According to the Centers for Disease Control And Prevention, skin diseases is the most common in the US and over 7% of skin related diseases that are tracked by skin cancer registries are adding fuel to the market growth.  


According to the WHO, millions of people worldwide are affected by neurological abnormalities or disorder. More than 6 million people die because of stroke each year; over 80% of deaths take place in low and middle income countries, which will boost the market growth in developing regions.


On the other hand, high cost of current treatment methods, and long duration for complete cure, for instance, it takes one-two years for facial growth and after facial growth the surgery is proceeded, which may hamper the market growth.   


The global Parry-Romberg syndrome market is expected to grow at a CAGR of approximately 7.8% during the forecast period 2017-2023.


Research Methodology
Parry-Romberg Syndrome Market
Source: World Health Organization, Centers for Disease Control and Prevention, expert interview market research future analysis, annual report, white paper, company presentation


Intended Audience



  • Pharmaceutical Companies

  • Medical Devices Manufacturer

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Segmentation   
The global Parry-Romberg syndrome market is segmented on the basis of diagnosis, treatment, and end user.


On the basis of diagnosis, the market is segmented into physical examination, MRI, serum test, and other.


On the basis of treatment, the market is categorized into drug treatment, surgery, and others. The drug treatment is further segmented into methotrexate, corticosteroids, cyclophosphamide, azathioprine, and others. The surgery is sub-segmented into orthognathic surgery, microsurgical reconstructive surgery, and others.


On the basis of end user, the market is segmented into hospitals & clinics, physical therapists, and others.


Key Players                                                                                   
Some of the key players in this market are DePuy Synthes (U.S.), Johnson & Johnson Services, Inc. (US), Medtronic (Ireland), Abbott (US), Immediate Media Company Ltd. (US), Taj Pharmaceuticals Ltd.,  Pfizer, Inc., Sanofi-Aventis, Biogen, Inc., GlaxoSmithKline, Inc., and AstraZeneca plc.    


Figure: Global Parry-Romberg Syndrome Market, by Region, 2016 (%)
Parry-Romberg Syndrome Market-


Source: World Health Organization, Centers for Disease Control and Prevention, expert interview market research future analysis, annual report, white paper, company presentation


 


Regional Analysis
The Americas dominates the global Parry-Romberg syndrome market owing to the presence of huge geriatric population, increasing number of patient with neurological disorder, eye related disorders. Moreover, high healthcare speeding, advanced hospitals infrastructures, availability of skilled healthcare professional are boosting the growth of the market.


Europe accounts for the second largest Parry-Romberg syndrome market across the globe owing to increasing government support for research & development, and increasing investment in healthcare. The countries such as France, and Germany investing in the healthcare to develop new diagnosis and treatment methods for rare diseases, which will boost the market growth. As per Organization for Economic Co-operation and Development (OECD), the share of GDP to health spending in Germany was 11.0% in 2013, compared with a share of GDP was up from 10.8% in 2012, which is responsible for the growth of the market in this region.


Asia Pacific has the fastest growing market, increasing government support for research & development, increasing prevalence of skin diseases, eye related diseases, and huge population base and rapidly developing economy drives the growth of the market in this region. Developing countries in this region are focusing more in the development of healthcare domain for instance country such as India.


The Middle East & Africa is expected to show the least market share due to less availability of medical facilities, and less development in healthcare domain. 



Frequently Asked Questions (FAQ) :


Parry-Romberg syndrome market is expected to register 7.8% CAGR from 2017 to 2023.

Parry-Romberg syndrome market is driven by rising incidence of skin conditions, neurological disorders, and eye defects.

Long waiting times for cures and high costs for treatments are factors which can hamper the global Parry-Romberg syndrome market.

The Americas can dominate the global Parry-Romberg syndrome market till 2023.

Medtronic, Johnson & Johnson Services, Inc., AstraZeneca plc Biogen, Inc., Pfizer, Inc., Sanofi-Aventis, DePuy Synthes, GlaxoSmithKline, Inc., Taj Pharmaceuticals Ltd., Abbott, and Immediate Media Company Ltd. are major players of the global Parry-Romberg syndrome market.

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Parry Romberg Syndrome Market, by Diagnosis

6.1 Introduction

6.2 Medical Examination

6.2.1 Market Estimates & Forecast, 2020-2027

6.3 MRI Scan

6.3.1 Market Estimates & Forecast, 2020-2027

6.4 Serum Test

6.4.1 Market Estimates & Forecast, 2020-2027

7. Global Parry Romberg Syndrome Market, by Treatment

7.1 Introduction

7.2 Drug Treatment

7.2.1 Market Estimates & Forecast, 2020-2027

7.3 Surgery

7.3.1 Market Estimates & Forecast, 2020-2027

8. Global Parry Romberg Syndrome Market, by End User

8.1 Introduction

8.2 Hospital & Clinics

8.2.1 Market Estimates & Forecast, 2020-2027

8.3 Physical Therapists

8.3.1 Market Estimates & Forecast, 2020-2027

9. Global Parry Romberg Syndrome Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 UK

9.3.1.4 Italy

9.3.1.5 Spain

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

11 Company Profiles

11.1 DePuy Synthes

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Johnson & Johnson Services, Inc

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Medtronic

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Abbott

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Immediate Media Company Ltd.

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Taj Pharmaceuticals Ltd.

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 Pfizer Inc.

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Others

12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Pharmaceutical Industry

13 Appendix

LIST OF TABLES

Table 1 Parry Romberg Syndrome Industry Synopsis, 2020-2027

Table 2 Global Parry Romberg Syndrome Market Estimates and Forecast, 2020-2027, (USD Million)

Table 3 Global Parry Romberg Syndrome Market by Region, 2020-2027, (USD Million)

Table 4 Global Parry Romberg Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 5 Global Parry Romberg Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 6 Global Parry Romberg Syndrome Market by End Users, 2020-2027, (USD Million)

Table 7 North America Parry Romberg Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 8 North America Parry Romberg Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 9 North America Parry Romberg Syndrome Market by End Users, 2020-2027, (USD Million)

Table 10 US Parry Romberg Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 12 US Parry Romberg Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 13 US Parry Romberg Syndrome Market by End Users, 2020-2027, (USD Million)

Table 14 Canada Parry Romberg Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 15 Canada Parry Romberg Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 16 Canada Parry Romberg Syndrome Market by End Users, 2020-2027, (USD Million)

Table 17 South America Parry Romberg Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 18 South America Parry Romberg Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 19 South America Parry Romberg Syndrome Market by End Users, 2020-2027, (USD Million)

Table 20 Europe Parry Romberg Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 21 Europe Parry Romberg Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 22 Europe Parry Romberg Syndrome Market by End Users, 2020-2027, (USD Million)

Table 23 Western Europe Parry Romberg Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 24 Western Europe Parry Romberg Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 25 Western Europe Parry Romberg Syndrome Market by End Users, 2020-2027, (USD Million)

Table 26 Eastern Europe Parry Romberg Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 27 Eastern Europe Parry Romberg Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 28 Eastern Europe Parry Romberg Syndrome Market by End Users, 2020-2027, (USD Million)

Table 29 Asia Pacific Parry Romberg Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 30 Asia Pacific Parry Romberg Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 31 Asia Pacific Parry Romberg Syndrome Market by End Users, 2020-2027, (USD Million)

Table 32 Middle East & Africa Parry Romberg Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 33 Middle East & Africa Parry Romberg Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 34 Middle East & Africa Parry Romberg Syndrome Market by End Users, 2020-2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Parry Romberg Syndrome Market

Figure 3 Segmentation Market Dynamics for Parry Romberg Syndrome Market

Figure 4 Global Parry Romberg Syndrome Market Share, by Diagnosis 2020

Figure 5 Global Parry Romberg Syndrome Market Share, by Treatment 2020

Figure 6 Global Parry Romberg Syndrome Market Share, by End Users, 2020

Figure 7 Global Parry Romberg Syndrome Market Share, by Region, 2020

Figure 8 North America Parry Romberg Syndrome Market Share, by Country, 2020

Figure 9 Europe Parry Romberg Syndrome Market Share, by Country, 2020

Figure 10 Asia Pacific Parry Romberg Syndrome Market Share, by Country, 2020

Figure 11 Middle East & Africa Parry Romberg Syndrome Market Share, by Country, 2020

Figure 12 Global Parry Romberg Syndrome Market: Company Share Analysis, 2020 (%)

Figure 13 DePuy Synthes: Key Financials

Figure 14 DePuy Synthes: Segmental Revenue

Figure 16 DePuy Synthes: Geographical Revenue

Figure 17 Johnson & Johnson Services, Inc: Key Financials

Figure 18 Johnson & Johnson Services, Inc: Segmental Revenue

Figure 19 Johnson & Johnson Services, Inc: Geographical Revenue

Figure 20 Medtronic: Key Financials

Figure 21 Medtronic: Segmental Revenue

Figure 22 Medtronic: Geographical Revenue

Figure 23 Abbott: Key Financials

Figure 24 Abbott: Segmental Revenue

Figure 25 Abbott: Geographical Revenue

Figure 26 Immediate Media Company Ltd.: Key Financials

Figure 27 Immediate Media Company Ltd.: Segmental Revenue

Figure 28 Immediate Media Company Ltd.: Geographical Revenue

Figure 29 Taj Pharmaceuticals Ltd.: Key Financials

Figure 30 Taj Pharmaceuticals Ltd.: Segmental Revenue

Figure 31 Taj Pharmaceuticals Ltd.: Geographical Revenue

Figure 32 Pfizer Inc: Key Financials

Figure 33 Pfizer Inc: Segmental Revenue

Figure 34 Pfizer Inc: Geographical Revenue